Literature DB >> 22059167

Clinical parameters predicting survival duration after hepatectomy for intrahepatic cholangiocarcinoma.

Bei-ge Jiang1, Rui-liang Ge, Liang-liang Sun, Ming Zong, Gong-tian Wei, Yong-jie Zhang.   

Abstract

BACKGROUND: Currently, the most effective treatment for intrahepatic cholangiocarcinoma (ICC) is complete hepatic tumour excision.
OBJECTIVE: To identify the clinical parameters associated with survival duration for ICC patients following hepatectomy, and to construct a mathematical model for predicting survival duration.
METHODS: Demographic data and clinical variables for 102 patients diagnosed with ICC, who underwent exploratory laparotomy at a single centre from July 1998 to December 2000 and were followed for an average of 24 months, were collected in 2011. Patients were randomly assigned into training (n=76) and validation (n=26) groups. Univariate and multivariate analyses were performed to identify factors associated with posthepatectomy survival duration.
RESULTS: Univariate analysis revealed that more than three lymph node metastases, a serum carbohydrate antigen 19-9 level greater than 37 U⁄mL, stage IVa tumours, and intra- or perihepatic metastases were significantly associated with decreased survival duration. Curative resection was significantly associated with increased survival duration. A mathematical model incorporating parameters of age, sex, metastatic lymph node number, curative surgery, carbohydrate antigen 19-9 concentration, alpha-fetoprotein concentration, hepatitis B, TNM stage and tumour differentiation was constructed for predicting survival duration. For a survival duration of less than one year, the model exhibited 93.8% sensitivity, 92.3% total accuracy and a positive predictive value of 93.8%; for a survival duration of one to three years, the corresponding values were 80.0%, 69.2% and 57.1%, respectively.
CONCLUSIONS: The mathematical model presented in the current report should prove to be useful in the clinical setting for predicting the extent to which curative resection affects the survival of ICC patients, and for selecting optimal postoperative treatment strategies.

Entities:  

Mesh:

Year:  2011        PMID: 22059167      PMCID: PMC3222769          DOI: 10.1155/2011/917097

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  25 in total

1.  Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma.

Authors:  M Shimada; Y Yamashita; S Aishima; K Shirabe; K Takenaka; K Sugimachi
Journal:  Br J Surg       Date:  2001-11       Impact factor: 6.939

2.  Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma.

Authors:  K Inoue; M Makuuchi; T Takayama; G Torzilli; J Yamamoto; K Shimada; T Kosuge; S Yamasaki; M Konishi; T Kinoshita; S Miyagawa; S Kawasaki
Journal:  Surgery       Date:  2000-05       Impact factor: 3.982

3.  Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes.

Authors:  S M Weber; W R Jarnagin; D Klimstra; R P DeMatteo; Y Fong; L H Blumgart
Journal:  J Am Coll Surg       Date:  2001-10       Impact factor: 6.113

4.  Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival.

Authors:  M Ohtsuka; H Ito; F Kimura; H Shimizu; A Togawa; H Yoshidome; M Miyazaki
Journal:  Br J Surg       Date:  2002-12       Impact factor: 6.939

5.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

6.  Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma.

Authors:  Yoshifumi Kawarada; Kentaro Yamagiwa; Bidhan C Das
Journal:  Am J Surg       Date:  2002-06       Impact factor: 2.565

7.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

8.  A long-term survivor of intrahepatic cholangiocarcinoma with lymph node metastasis: a case report.

Authors:  Masakazu Yamamoto; Ken Takasaki; Toshihide Imaizumi; Shunichi Ariizumi; Naoki Matsumura; Masayuki Nakano
Journal:  Jpn J Clin Oncol       Date:  2002-06       Impact factor: 3.019

9.  Retrospective analysis of histopathologic prognostic factors after hepatectomy for intrahepatic cholangiocarcinoma.

Authors:  Bei-Ge Jiang; Liang-Liang Sun; Wen-Long Yu; Zhao-Hui Tang; Ming Zong; Yong-Jie Zhang
Journal:  Cancer J       Date:  2009 May-Jun       Impact factor: 3.360

10.  Worldwide trends in mortality from biliary tract malignancies.

Authors:  Tushar Patel
Journal:  BMC Cancer       Date:  2002-05-03       Impact factor: 4.430

View more
  8 in total

1.  Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors.

Authors:  Shigeru Marubashi; Kunihito Gotoh; Hidenori Takahashi; Hiroaki Ohigashi; Masahiko Yano; Osamu Ishikawa; Masato Sakon
Journal:  Dig Dis Sci       Date:  2014-01       Impact factor: 3.199

Review 2.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 3.  Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis.

Authors:  Zheng Wang; Yuan-Yuan Sheng; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

Review 4.  HBV Infection Status and the Risk of Cholangiocarcinoma in Asia: A Meta-Analysis.

Authors:  Hao Zhang; Biqing Zhu; He Zhang; Jianxin Liang; Wenting Zeng
Journal:  Biomed Res Int       Date:  2016-11-23       Impact factor: 3.411

Review 5.  Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Seogsong Jeong; Ying Tong; Meng Sha; Jinyang Gu; Qiang Xia
Journal:  Oncotarget       Date:  2017-03-07

6.  Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis.

Authors:  Meng Sha; Seogsong Jeong; Xiao-Song Chen; Ying Tong; Jie Cao; Han-Yong Sun; Lei Xia; Ning Xu; Xin Wang; Long-Zhi Han; Zhi-Feng Xi; Jian-Jun Zhang; Xiao-Ni Kong; Qiang Xia
Journal:  Int J Biol Sci       Date:  2018-07-27       Impact factor: 6.580

7.  Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against Cholangiocarcinoma.

Authors:  Zhiqiang Chen; Tong Lin; Xiaozhong Liao; Zeyun Li; Ruiting Lin; Xiangjun Qi; Guoming Chen; Lingling Sun; Lizhu Lin
Journal:  Chin Med       Date:  2021-01-21       Impact factor: 5.455

8.  Radiotherapy prolongs biliary metal stent patency in malignant pancreatobiliary obstructions.

Authors:  Semi Park; Jeong Youp Park; Seungmin Bang; Seung Woo Park; Jae Bock Chung; Si Young Song
Journal:  Gut Liver       Date:  2013-06-11       Impact factor: 4.519

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.